Comparative Pharmacology
Head-to-head clinical analysis: ERYPED versus ERYTHROMYCIN AND BENZOYL PEROXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYPED versus ERYTHROMYCIN AND BENZOYL PEROXIDE.
ERYPED vs ERYTHROMYCIN AND BENZOYL PEROXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It is a macrolide antibiotic.
Erythromycin is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. Benzoyl peroxide has bactericidal effects against Propionibacterium acnes, likely through the release of free radical oxygen that oxidizes bacterial proteins. It also has keratolytic and comedolytic properties.
250–500 mg orally every 6 hours or 500–1000 mg intravenously every 6 hours; maximum 4 g/day.
Topical: Apply a thin layer to affected areas once daily in the evening.
None Documented
None Documented
2-4 hours (prolonged to 4-6 hours in neonates and patients with hepatic impairment); requires q6h dosing for most indications.
Erythromycin: 1.4–2.0 hours (terminal half-life in adults). Benzoyl peroxide: Not applicable; it is a topical agent with negligible systemic absorption.
Primarily hepatic (biliary excretion of unchanged drug and metabolites); approximately 5% renal excretion as unchanged drug.
Erythromycin is primarily excreted via bile (fecal elimination) with approximately 15% excreted unchanged in urine. Benzoyl peroxide is degraded to benzoic acid, which is conjugated with glycine to form hippuric acid and excreted renally; less than 5% is excreted unchanged in urine.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic